Literature DB >> 21557394

miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes.

Joel R Pekow1, Urszula Dougherty, Reba Mustafi, Hongyan Zhu, Masha Kocherginsky, David T Rubin, Stephen B Hanauer, John Hart, Eugene B Chang, Alessandro Fichera, Loren J Joseph, Marc Bissonnette.   

Abstract

BACKGROUND: miR-143 and miR-145 are believed to function as colon cancer tumor suppressors, as they inhibit colon cancer cell growth and are downregulated in sporadic colonic tumors. We speculated that miR-143 and miR-145 might also be downregulated and contribute to malignant transformation of colonic epithelium in longstanding ulcerative colitis (UC).
METHODS: Biopsies were obtained 20 cm proximal to the anus from individuals with quiescent UC and from normal controls. RNA and proteins were extracted and measured. miR-143 and miR-145 were quantified by real-time polymerase chain reaction (PCR) and miR-145 was also assessed by in situ hybridization. Putative targets of these miRNAs, K-RAS, API5, MEK-2 (miR-143), and IRS-1 (miR-145) were determined by western blotting. To assess the effects of miR-143 and miR-145 on these predicted targets, HCT116 and HCA-7 colorectal cancer cells were transfected with miR-143 and miR-145 and expression levels of these proteins were measured.
RESULTS: In UC, miR-143 and miR-145 were significantly downregulated 8.3-fold (3.4-20.1) (P < 0.0001) and 4.3-fold (2.3-7.8) (P < 0.0001), respectively, compared to normal colon. In contrast, IRS-1, K-RAS, API5, and MEK-2 were upregulated in UC, consistent with their assignments as targets of these miRNAs. Furthermore, transfected miR-143 and miR-145 significantly downregulated these proteins in HCT116 or HCA-7 cells.
CONCLUSIONS: Compared to normal colonic mucosa, in chronic UC miR-143 and miR-145 were significantly downregulated and their predicted targets, IRS-1, K-RAS, API5, and MEK-2 were upregulated. We postulate that loss of these tumor suppressor miRNAs predispose to chronic inflammation and neoplastic progression in IBD.
Copyright © 2011 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21557394      PMCID: PMC3931730          DOI: 10.1002/ibd.21742

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  56 in total

Review 1.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

2.  Role of miR-143 targeting KRAS in colorectal tumorigenesis.

Authors:  X Chen; X Guo; H Zhang; Y Xiang; J Chen; Y Yin; X Cai; K Wang; G Wang; Y Ba; L Zhu; J Wang; R Yang; Y Zhang; Z Ren; K Zen; J Zhang; C-Y Zhang
Journal:  Oncogene       Date:  2009-01-12       Impact factor: 9.867

3.  Identifying targets of miR-143 using a SILAC-based proteomic approach.

Authors:  Yi Yang; Raghothama Chaerkady; Kumaran Kandasamy; Tai-Chung Huang; Lakshmi Dhevi N Selvan; Sutopa B Dwivedi; Oliver A Kent; Joshua T Mendell; Akhilesh Pandey
Journal:  Mol Biosyst       Date:  2010-06-14

4.  Enhanced expression of proproliferative and antiapoptotic genes in ulcerative colitis-associated neoplasia.

Authors:  Jirí Svec; Jana Musílková; Jana Bryndová; Tomás Jirásek; Václav Mandys; Milan Kment; Jirí Pácha
Journal:  Inflamm Bowel Dis       Date:  2010-07       Impact factor: 5.325

5.  Increased expression of microRNA in the inflamed colonic mucosa of patients with active ulcerative colitis.

Authors:  Tomohisa Takagi; Yuji Naito; Katsura Mizushima; Ikuhiro Hirata; Nobuaki Yagi; Naoya Tomatsuri; Takashi Ando; Yuichi Oyamada; Yutaka Isozaki; Hitoshi Hongo; Kazuhiko Uchiyama; Osamu Handa; Satoshi Kokura; Hiroshi Ichikawa; Toshikazu Yoshikawa
Journal:  J Gastroenterol Hepatol       Date:  2010-05       Impact factor: 4.029

6.  Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease.

Authors:  Magali Fasseu; Xavier Tréton; Cécile Guichard; Eric Pedruzzi; Dominique Cazals-Hatem; Christophe Richard; Thomas Aparicio; Fanny Daniel; Jean-Claude Soulé; Richard Moreau; Yoram Bouhnik; Marc Laburthe; André Groyer; Eric Ogier-Denis
Journal:  PLoS One       Date:  2010-10-05       Impact factor: 3.240

7.  Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy.

Authors:  David M Su; Qiuyang Zhang; Xuexi Wang; Ping He; Yuelin Jack Zhu; Jianxiong Zhao; Owen M Rennert; Yan A Su
Journal:  Mol Cancer Ther       Date:  2009-04-21       Impact factor: 6.261

8.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

9.  Insulin receptor substrate-1 deficiency promotes apoptosis in the putative intestinal crypt stem cell region, limits Apcmin/+ tumors, and regulates Sox9.

Authors:  Nicole M Ramocki; Heather R Wilkins; Scott T Magness; James G Simmons; Brooks P Scull; Ginny H Lee; Kirk K McNaughton; P Kay Lund
Journal:  Endocrinology       Date:  2007-10-04       Impact factor: 4.736

10.  Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype.

Authors:  Daniel T Starczynowski; Florian Kuchenbauer; Bob Argiropoulos; Sandy Sung; Ryan Morin; Andrew Muranyi; Martin Hirst; Donna Hogge; Marco Marra; Richard A Wells; Rena Buckstein; Wan Lam; R Keith Humphries; Aly Karsan
Journal:  Nat Med       Date:  2009-11-08       Impact factor: 53.440

View more
  51 in total

Review 1.  Immunopathogenesis of IBD: current state of the art.

Authors:  Heitor S P de Souza; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-02       Impact factor: 46.802

2.  EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators.

Authors:  Hongyan Zhu; Urszula Dougherty; Victoria Robinson; Reba Mustafi; Joel Pekow; Sonia Kupfer; Yan Chun Li; John Hart; Kathleen Goss; Alessandro Fichera; Loren Joseph; Marc Bissonnette
Journal:  Mol Cancer Res       Date:  2011-06-08       Impact factor: 5.852

Review 3.  Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy.

Authors:  Weiwei Jiang; Xuhang Li
Journal:  Mol Diagn Ther       Date:  2015-06       Impact factor: 4.074

4.  Rectal microRNAs are perturbed in pediatric inflammatory bowel disease of the colon.

Authors:  Adam M Zahm; Nicholas J Hand; Daphne M Tsoucas; Claire L Le Guen; Robert N Baldassano; Joshua R Friedman
Journal:  J Crohns Colitis       Date:  2014-03-07       Impact factor: 9.071

5.  miR-4728-3p Functions as a Tumor Suppressor in Ulcerative Colitis-associated Colorectal Neoplasia Through Regulation of Focal Adhesion Signaling.

Authors:  Joel Pekow; Alan L Hutchison; Katherine Meckel; Kymberly Harrington; Zifeng Deng; Nitya Talasila; David T Rubin; Stephen B Hanauer; Roger Hurst; Konstantin Umanskiy; Alessandro Fichera; John Hart; Aaron R Dinner; Marc Bissonnette
Journal:  Inflamm Bowel Dis       Date:  2017-08       Impact factor: 5.325

Review 6.  How microRNAs influence both hereditary and inflammatory-mediated colon cancers.

Authors:  Jennifer Hutchison; Zoe Cohen; Benjamin C Onyeagucha; Janet Funk; Mark A Nelson
Journal:  Cancer Genet       Date:  2013-09-14

7.  Downregulation of microRNA-107 in intestinal CD11c(+) myeloid cells in response to microbiota and proinflammatory cytokines increases IL-23p19 expression.

Authors:  Xiaochang Xue; Anthony T Cao; Xiaocang Cao; Suxia Yao; Eric D Carlsen; Lynn Soong; Chang-Gong Liu; Xiuping Liu; Zhanju Liu; L Wayne Duck; Charles O Elson; Yingzi Cong
Journal:  Eur J Immunol       Date:  2014-01-13       Impact factor: 5.532

8.  Apoptosis inhibitor 5 (API-5; AAC-11; FIF) is upregulated in human carcinomas in vivo.

Authors:  Lenka Koci; Katarina Chlebova; Martina Hyzdalova; Jirina Hofmanova; Miroslav Jira; Petr Kysela; Alois Kozubik; Zdenek Kala; Pavel Krejci
Journal:  Oncol Lett       Date:  2012-02-03       Impact factor: 2.967

Review 9.  MicroRNAs in inflammatory bowel disease--pathogenesis, diagnostics and therapeutics.

Authors:  Mehmet Coskun; Jacob Tveiten Bjerrum; Jakob Benedict Seidelin; Ole Haagen Nielsen
Journal:  World J Gastroenterol       Date:  2012-09-14       Impact factor: 5.742

10.  Identification of serum and tissue micro-RNA expression profiles in different stages of inflammatory bowel disease.

Authors:  M Iborra; F Bernuzzi; C Correale; S Vetrano; G Fiorino; B Beltrán; F Marabita; M Locati; A Spinelli; P Nos; P Invernizzi; S Danese
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.